Sjoerd Klarenbeek

12PUBLICATIONS
76CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsCancer diagnosisDevelopmental genetics (incl. sex determination)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Dec 29, 2025
C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3.

Julia Yemelyanenko, Jinhyuk Bhin, Eline van der Burg

|Jun 24, 2025
The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2.

Daniel Zingg, Chi-Chuan Lin, Julia Yemelyanenko

|Aug 29, 2023
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

Jinhyuk Bhin, Julia Yemelyanenko, Xue Chao

|Jan 12, 2023
CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer.

Julia M Houthuijzen, Roebi de Bruijn, Eline van der Burg

|Sep 01, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko

|Aug 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko

Pageof 2

Frequent Collaborators

10 joint publications

Jos Jonkers

6 joint publications

Lodewyk F A Wessels

6 joint publications

Daniel Zingg

5 joint publications

Jinhyuk Bhin